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Background: Treatment strategy for patients presenting with femoropopliteal artery (FP) lesions remains controversial. Recently, nitinol stenting 
in the FP lesions has yielded improved mid-term results. The purpose of this study was to investigate the long-term outcomes of nitinol stent 
implantation in FP lesions as long as 6 years and to determine the factors associated with the restenosis in FP lesions.
Methods: Between December 2003 and December 2009, 861 patients with 1085 FP lesions in 1061 limbs (mean age 72 years; 69% male) 
underwent nitinol stent implantation. Restenosis was defined either by duplex ultrasound (peak systolic velocity > 2.4), or angiography (>50%). 
Patency was analyzed by Kaplan-Meier estimation.
Results: Mean (±SD) length of the treated segments was 152±93mm. Stent fracture occurred in 9.9% of lesions. At 1, 2, 3, 4, 5, and 6 years, the 
primary patency rates were 77.2%, 70.3%, 66.2%, 65.0%, 64.0% and 62.0%; secondary patency rates, 90.5%, 88.0%, 87.1%, 86.3%, 86.3%, and 
86.3%, respectively. By multivariable Cox regression analysis, female (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.27-2.09; P=0.0001), 
the absence of cilostasol administration (HR, 1.90; CI, 95% CI, 1.48-2.43; P<0.0001), stent fracture (HR, 1.54; 95%CI, 1.10-2.18; P=0.013), and 
TransAtlantic Inter-Society Consensus (TASC) C+D lesion (HR, 2.23; 95% CI 1.48-3.37; P=0.0001) were the strong independent factors associated 
with restenosis.
Conclusions: Endovascular therapy using nitinol stents for FP lesions yielded acceptable outcomes as long as 6 years.
